,address1,address2,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,trailingPE,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,697 Burke Road,Suite 201,Camberwell,VIC,3124,Australia,61 3 9092 0480,64 9 3617 981,https://www.neurenpharma.com,Biotechnology,Healthcare,"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.","{'maxAge': 1, 'name': 'Mr. Jonathan Charles Pilcher A.C.A., ACA, B.Sc., BSc (Hons), F.C.A.', 'title': 'CEO, MD & Exec. Director', 'fiscalYear': 2022, 'totalPay': 420833, 'exercisedValue': 0, 'unexercisedValue': 0}",8,7,6,1,6,1693526400,1672444800,86400,2,11.28,11.43,11.0,11.48,11.28,11.43,11.0,11.48,0.0,1.514264,26.190477,23.404255,4257489,4257489,626286,1333675,1333675,10.97,11.06,0,0,1454727936,6.05,15.15,18.568703,12.4466,11.21685,0.0,0.0,AUD,1306547456,0.70259005,108838887,128966000,0.14002,0.12948,0.723,15.214385,1672444800,1703980800,1688083200,55043000,0.42,0.47,1:20,1511222400,16.677,23.86,ASX,EQUITY,NEU.AX,NEU.AX,NEUREN FPO NZ,Neuren Pharmaceuticals Limited,1107298800,Australia/Sydney,AEST,36000000,11.0,22.21,6.72,16.56,18.3,2.2,buy,5,85675000,0.677,54760000,0,16.018,16.04,78343000,0.621,0.518,0.88064003,2705000,33750500,54293000,0.75504,0.69898003,0.69882005,AUD,
1,697 Burke Road,Suite 201,Camberwell,VIC,3124,Australia,61 3 9092 0480,64 9 3617 981,https://www.neurenpharma.com,Biotechnology,Healthcare,"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.","{'maxAge': 1, 'name': 'Ms. Lauren  Frazer C.A.', 'title': 'CFO & Company Sec.', 'exercisedValue': 0, 'unexercisedValue': 0}",8,7,6,1,6,1693526400,1672444800,86400,2,11.28,11.43,11.0,11.48,11.28,11.43,11.0,11.48,0.0,1.514264,26.190477,23.404255,4257489,4257489,626286,1333675,1333675,10.97,11.06,0,0,1454727936,6.05,15.15,18.568703,12.4466,11.21685,0.0,0.0,AUD,1306547456,0.70259005,108838887,128966000,0.14002,0.12948,0.723,15.214385,1672444800,1703980800,1688083200,55043000,0.42,0.47,1:20,1511222400,16.677,23.86,ASX,EQUITY,NEU.AX,NEU.AX,NEUREN FPO NZ,Neuren Pharmaceuticals Limited,1107298800,Australia/Sydney,AEST,36000000,11.0,22.21,6.72,16.56,18.3,2.2,buy,5,85675000,0.677,54760000,0,16.018,16.04,78343000,0.621,0.518,0.88064003,2705000,33750500,54293000,0.75504,0.69898003,0.69882005,AUD,
2,697 Burke Road,Suite 201,Camberwell,VIC,3124,Australia,61 3 9092 0480,64 9 3617 981,https://www.neurenpharma.com,Biotechnology,Healthcare,"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.","{'maxAge': 1, 'name': 'Mr. Lawrence  Glass BA (Biology)', 'title': 'Chief Science Officer', 'fiscalYear': 2019, 'exercisedValue': 0, 'unexercisedValue': 0}",8,7,6,1,6,1693526400,1672444800,86400,2,11.28,11.43,11.0,11.48,11.28,11.43,11.0,11.48,0.0,1.514264,26.190477,23.404255,4257489,4257489,626286,1333675,1333675,10.97,11.06,0,0,1454727936,6.05,15.15,18.568703,12.4466,11.21685,0.0,0.0,AUD,1306547456,0.70259005,108838887,128966000,0.14002,0.12948,0.723,15.214385,1672444800,1703980800,1688083200,55043000,0.42,0.47,1:20,1511222400,16.677,23.86,ASX,EQUITY,NEU.AX,NEU.AX,NEUREN FPO NZ,Neuren Pharmaceuticals Limited,1107298800,Australia/Sydney,AEST,36000000,11.0,22.21,6.72,16.56,18.3,2.2,buy,5,85675000,0.677,54760000,0,16.018,16.04,78343000,0.621,0.518,0.88064003,2705000,33750500,54293000,0.75504,0.69898003,0.69882005,AUD,
3,697 Burke Road,Suite 201,Camberwell,VIC,3124,Australia,61 3 9092 0480,64 9 3617 981,https://www.neurenpharma.com,Biotechnology,Healthcare,"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.","{'maxAge': 1, 'name': 'Mr. Gerry  Zhao', 'title': 'VP of Corp. Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",8,7,6,1,6,1693526400,1672444800,86400,2,11.28,11.43,11.0,11.48,11.28,11.43,11.0,11.48,0.0,1.514264,26.190477,23.404255,4257489,4257489,626286,1333675,1333675,10.97,11.06,0,0,1454727936,6.05,15.15,18.568703,12.4466,11.21685,0.0,0.0,AUD,1306547456,0.70259005,108838887,128966000,0.14002,0.12948,0.723,15.214385,1672444800,1703980800,1688083200,55043000,0.42,0.47,1:20,1511222400,16.677,23.86,ASX,EQUITY,NEU.AX,NEU.AX,NEUREN FPO NZ,Neuren Pharmaceuticals Limited,1107298800,Australia/Sydney,AEST,36000000,11.0,22.21,6.72,16.56,18.3,2.2,buy,5,85675000,0.677,54760000,0,16.018,16.04,78343000,0.621,0.518,0.88064003,2705000,33750500,54293000,0.75504,0.69898003,0.69882005,AUD,
4,697 Burke Road,Suite 201,Camberwell,VIC,3124,Australia,61 3 9092 0480,64 9 3617 981,https://www.neurenpharma.com,Biotechnology,Healthcare,"Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.","{'maxAge': 1, 'name': 'Dr. Liza A. Squires M.D.', 'title': 'Chief Medical Officer', 'exercisedValue': 0, 'unexercisedValue': 0}",8,7,6,1,6,1693526400,1672444800,86400,2,11.28,11.43,11.0,11.48,11.28,11.43,11.0,11.48,0.0,1.514264,26.190477,23.404255,4257489,4257489,626286,1333675,1333675,10.97,11.06,0,0,1454727936,6.05,15.15,18.568703,12.4466,11.21685,0.0,0.0,AUD,1306547456,0.70259005,108838887,128966000,0.14002,0.12948,0.723,15.214385,1672444800,1703980800,1688083200,55043000,0.42,0.47,1:20,1511222400,16.677,23.86,ASX,EQUITY,NEU.AX,NEU.AX,NEUREN FPO NZ,Neuren Pharmaceuticals Limited,1107298800,Australia/Sydney,AEST,36000000,11.0,22.21,6.72,16.56,18.3,2.2,buy,5,85675000,0.677,54760000,0,16.018,16.04,78343000,0.621,0.518,0.88064003,2705000,33750500,54293000,0.75504,0.69898003,0.69882005,AUD,
